$0.07
(0.87%)
Add to watchlist
Create an alert
Stocks and Shares ISAVerrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).
Company Information
About this company
Key people
Jayson Rieger
President, Chief Executive Officer, Director
John J. Kirby
Interim Chief Financial Officer, Interim Principal Financial Officer
David Zawitz
Chief Operating Officer
Noah L. Rosenberg
Chief Medical Officer
Paul B. Manning
Chairman of the Board
Charles Frantzreb
Director
Gavin Corcoran
Independent Director
Lawrence Eichenfield
Independent Director
Diem Nguyen
Independent Director
Click to see more
Key facts
- Shares in issue16.00m
- EPICVRCA
- ISINUS92511W2070
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$128.72m
- Employees71
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.